ArticleScientific reports2026
Assessment of breast cancer and feasibility of subtyping of breast cancer using thoracoabdominal staging photon-counting detector computed tomography.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this prospective study, we evaluated the performance of thoracoabdominal photon-counting detector computed tomography (PCD-CT) for breast cancer assessment with MRI as reference standard and iodine uptake as a potential marker for breast cancer subtyping. 75 women (mean age: 55.8 ± 13.9 years [SD]) with 79 newly diagnosed breast cancers and indication for staging CT received a prone-positioned contrast-enhanced thoracoabdominal PCD-CT and a breast MRI. Cancer visibility (median 1/1/1, IQR 0/1/1) and image quality (median 1/1/1, IQR 0/0/0) were rated excellent in PCD-CT on a 4-point Likert scale (1 = excellent, 4 = poor). Cancer size in PCD-CT correlated significantly with MRI (p < 0.001). Diagnostic accuracy was good for T-stage (pooled accuracy 0.814), focality (0.772), axillary (0.822) and internal mammary lymph nodes (0.981), moderate for ductal carcinoma in situ (0.591). A significantly lower maximum iodine uptake was revealed in cancer with ductal carcinoma in situ (p = 0.027), a significantly lower mean iodine uptake in triple negative cancers (p = 0.003). Thoracoabdominal PCD-CT demonstrated excellent cancer visibility with convincing results for assessing cancer size, T-stage, and lymph node status. Iodine uptake shows promising associations with triple negative breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.